SCHEMBL6921783

SCHEMBL6921783

O=c1c2ccc(-c3ccc(F)cc3)cc2ncn1C1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVR1 Q04771 1/20 0.50
HSD17B10 Q99714 3/20 0.48
KDM4E B2RXH2 2/20 0.48
NPC1 O15118 2/20 0.48
ALDH1A1 P00352 2/20 0.48
RAB9A P51151 2/20 0.48
SLC2A1 P11166 1/20 0.48
BTK Q06187 2/20 0.43
HCAR1 Q9BXC0 5/20 0.42
MAPK14 Q16539 3/20 0.41
MAPK13 O15264 2/20 0.41
MAPK12 P53778 2/20 0.41
MAPK11 Q15759 2/20 0.41
EGFR P00533 1/20 0.41
CSNK1D P48730 1/20 0.41
CSNK1E P49674 1/20 0.41
KCNH2 Q12809 1/20 0.41
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.39
TGFBR1 P36897 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059745 0.89 ACVR1 (0.50) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL2054288 0.84 HSD17B10 (0.46) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL6920715 0.79 ACVR1 (0.48) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL25151753 0.77 ACVR1 (0.50) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL6921895 0.76 GRM5 (0.49) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL25151758 0.76 ACVR1 (0.49) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL25151865 0.76 ACVR1 (0.49) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL25151871 0.76 ACVR1 (0.49) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL25151867 0.76 ACVR1 (0.49) ACVR1HSD17B10KDM4ENPC1ALDH1A1
SCHEMBL6921950 0.76 MAPK14 (0.47) ALDH1A1SLC2A1MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 ACVR1 4208/4885HSD17B10 2253/4885KDM4E 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.